• Tonix highlighted TONMYA, a sublingual cyclobenzaprine product launched Nov. 17, 2025 for fibromyalgia in adults.
• Cash and cash equivalents of about $185.5 million as of March 31, 2026; no debt; runway expected into early Q2 2027.
• TONMYA net sales of $3.7 million in Q1 2026; $5.1 million from Nov. 17, 2025 to March 31, 2026.
• Since launch, more than 2,600 prescribers; about 11,016 prescriptions through May 1, 2026; about 5,618 patients through April 24, 2026.
• Pipeline updates include TNX-4800 Lyme prevention Phase 2 planned Q1 2027; TNX-1500 transplant rejection Phase 2 planned 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein.